What “best market” actually means
Teams usually ask which market is biggest. The more useful question is which market converts your existing evidence into authorized, paid-for sales with the least additional spend. Four forces decide that: how hard the regulatory route is, whether a payment pathway exists, how entrenched the competition is, and what it costs to operate there.
A market that is large but demands a fresh clinical study, local testing and a distributor network can be a worse first move than a smaller market that recognizes evidence you already hold.
The factors that decide it
| Factor | What to ask | Why it moves the decision |
|---|---|---|
| Regulatory route | Which classification and submission type applies? | Sets timeline, cost and the evidence you must produce. |
| Evidence portability | Does this regulator accept authorizations or data from elsewhere? | Decides whether you pay for evidence once or twice. |
| Reimbursement | Is there a code, coverage and an actual payment amount? | Clearance without payment produces no revenue. |
| Market size | What is the addressable population and procedure volume? | Caps the commercial ceiling. |
| Competitive intensity | Who holds the category and how switchable are buyers? | Determines sales cycle length and pricing power. |
| Clinical ecosystem | Are there trial sites and reference centres? | Affects evidence generation speed and credibility. |
| Policy momentum | Are there incentives or digital-health programs? | Can shorten review or unlock funded pilots. |
| Localization burden | Language, labeling, local representative, data residency? | Adds hidden fixed cost per market. |
| Supply chain | Where is manufacturing relative to the market? | Drives landed cost and tariff exposure. |
| Operating cost | Distributor margins, service, support footprint? | Sets the true breakeven volume. |
Weighting matters as much as scoring. A software-only diagnostic weights data-residency rules and reimbursement heavily; an implantable weights clinical evidence and review timelines heavily. Fixed weights across every device type are the most common flaw in market-selection spreadsheets.
How the major markets compare
| Market | Regulatory character | Best suited to |
|---|---|---|
| United States | FDA 510(k), De Novo or PMA; predicate-driven for most Class II devices | Devices with a clear predicate and evidence that will later travel to other regions. |
| European Union | EU MDR with notified-body review; CE marking covers 27 countries | Teams with clinical evidence in hand and patience for notified-body capacity. |
| United Kingdom | UKCA route alongside recognition arrangements for CE-marked devices | Companies already pursuing the EU, as an adjacent step. |
| Japan | PMDA review with structured reimbursement pricing | High-value devices where a committed local partner is available. |
| Gulf (UAE and neighbours) | Registration routes that lean on FDA or CE authorizations | Fast follow-on entry once you hold FDA or CE evidence. |
Requirements change. Confirm the current route with each regulator before committing budget — FDA, the European Commission, MHRA, PMDA and the relevant national authority all publish current guidance.
Worked example: a remote cardiac monitor
Take a wearable remote cardiac monitor with software analysis, no implantable component, and comparable cleared devices already on the US market.
- Regulatory route: predicates exist, so a 510(k) is the likely US path — search the FDA 510(k) database for comparable monitors before assuming it.
- Evidence portability: US clearance plus a quality system gives a strong base for Gulf registration and supports an EU technical file.
- Reimbursement: remote monitoring payment matters more than clearance here; a market with no remote-monitoring payment pathway is a poor first choice regardless of size.
- Localization: as connected software, data-residency and privacy rules are a first-order constraint, not an afterthought.
- Likely sequence: United States first, then a Gulf or Australia-style recognition market, with the EU planned around notified-body availability.
Change one input — make it implantable, or remove the predicate — and the sequence changes. That is the point: the answer is device-specific, which is exactly what a scoring model should capture.
Common mistakes
- Ranking markets by population or spend and stopping there.
- Treating reimbursement as a post-clearance problem.
- Assuming FDA clearance means quick EU entry.
- Using the same dimension weights for every device in the portfolio.
- Deciding once, instead of setting decision gates that trigger the next market.
How MedTechCompass scores this for your device
MedTechCompass starts from curated market baselines for each of ten dimensions, then applies a bounded, evidence-cited adjustment specific to your device description — so every score shows a baseline, an adjustment and the reason behind it. Weights are selected automatically from your device profile and regulatory pathway, with manual presets available as an override.
The output is a ranked market list and a single-market report with a 90-day entry plan, decision gates and a source appendix. Start with the free Regulatory Analyzer to fix classification and pathway, then run the market comparison.
Frequently asked questions
Which is the best market for a medical device overall?
There is no universal answer. The United States offers the largest single market and the most portable evidence, but the best first market is the one where your existing evidence, your reimbursement prospects and your operating budget line up.
How do I compare markets objectively?
Score each candidate on the same explicit factors — regulatory route, evidence portability, reimbursement, size, competition, clinical ecosystem, policy, localization, supply chain and operating cost — and weight those factors to match your device type rather than debating markets anecdotally.
Does the FDA 510(k) database help with market choice?
Yes, indirectly. Finding comparable cleared devices tells you whether a predicate-based route is realistic in the US and reveals who already competes in the category, which feeds both the regulatory and competitive factors.
When does Europe make more sense than the United States?
When your clinical evidence is already aligned to EU MDR expectations, your commercial partners are European, or your category faces a difficult US predicate situation. Plan around notified-body capacity, which is often the binding constraint.
How many markets should I target at once?
Plan a sequence of three to five, execute one or two at a time, and attach explicit milestones that trigger the next entry. Parallel filings usually dilute budget and management attention.
Related reading
Go deeper with MedTechCompass
Describe your device in plain language and get an AI-assisted triage: likely FDA class, product codes, premarket pathway, EU MDR and UK considerations — plus market attractiveness scoring across curated global markets.
This article is educational content from CAHIR Solutions and is not legal or regulatory advice. Regulatory decisions depend on your specific intended use and claims — confirm them with FDA resources, a qualified consultant, or a pre-submission meeting before filing.